GLYCOFI/CENTOCOR EVALUATE GLYCOPROTEIN PRODUCTION.
GlycoFi, Inc. is a biotechnology company that leverages its pioneering protein production technology to develop, produce and commercialize next generation biotherapeutics, alone and in partnership with other leading biopharmaceutical companies.
About GlycoFi's Technology
Sugars, or glycosylation, on the surface of a protein are known to influence critical pharmaceutical properties of therapeutic proteins and monoclonal antibodies. GlycoFi is the leader in the area of glycosylation engineering in living systems, and its patented, scaleable technology uniquely allows its partners to create specific human glycosylation variants of any therapeutic glycoprotein. For the first time, GlycoFi and its partners can systematically research the impact of a protein's glycovariants on its pharmaceutical properties, enabling the optimization of biological activity, receptor binding, serum half-life, and potency of the drug candidate, thereby reducing the overall development risk of the project.
For more information, visit http://www.glycofi.com or call 603/643-8186, ext. 106.
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 1, 2005|
|Previous Article:||NUVELO BEGINS PHASE 3 TRIAL OF ALFIMEPRASE FOR "LEG ATTACK".|
|Next Article:||MAP PHARMACEUTICALS APPOINTS NELSON PRESIDENT/CEO.|